| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Surgery [L. L, P. B.] and Oncology [P. B.], McGill University and the Royal Victoria Hospital [P. B.], Montreal, Quebec, Canada H3A 1A4; and Department of Pathology and Cell Biology, Jefferson Medical College [R. R.], and Jefferson Cancer Institute [R. B.], Thomas Jefferson University, Philadelphia, Pennsylvania 19107
The ability of malignant cells to form metastases in secondary sites remains a major obstacle to the curative treatment of cancer. Previously, we identified type 1 insulin-like growth factor (IGF-1) as a paracrine mitogen for highly metastatic murine carcinoma, H-59 cells. Here the role of IGF-1 and its receptor (IGF-1R) in metastasis was further investigated using H-59 cells transfected with a plasmid vector expressing IGF-1R cDNA in the antisense orientation. The transfectants had a markedly reduced expression of IGF-1R and lost the ability to respond to IGF-1 in vitro. When injected in vivo, either directly into the microvasculature of the liver or lung (experimental metastasis) or s.c. to allow the growth of primary local tumors (spontaneous metastasis), these cells did not give rise to any metastases under conditions which allowed wild-type or control transfectants to form multiple hepatic and pulmonary metastases. The results demonstrate that the IGF-1R can play a critical role in the regulation of carcinoma metastasis.
1 This work was supported by a grant from the Medical Research Council of Canada (to P. B.) and also by NIH Grants AA-0123 and AA-07309 (to R. R.) and CA-53484 (to R. B.)
2 To whom requests for reprints should be addressed.
Received 12/20/94. Accepted 1/19/95.
This article has been cited by other articles:
|
|
 |
|
  M. C. Manara, L. Landuzzi, P. Nanni, G. Nicoletti, D. Zambelli, P. L. Lollini, C. Nanni, F. Hofmann, C. Garcia-Echeverria, P. Picci, et al. Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor-Specific Inhibitor in Ewing's Sarcoma Clin. Cancer Res., February 15, 2007; 13(4): 1322 - 1330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Wang, T. Thuraisingam, L. Fallavollita, A. Ding, D. Radzioch, and P. Brodt The Secretory Leukocyte Protease Inhibitor Is a Type 1 Insulin-Like Growth Factor Receptor-Regulated Protein that Protects against Liver Metastasis by Attenuating the Host Proinflammatory Response. Cancer Res., March 15, 2006; 66(6): 3062 - 3070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Martin, N. Melnyk, M. Pollard, M. Bowden, H. Leong, T. J. Podor, M. Gleave, and P. H. B. Sorensen The Insulin-Like Growth Factor I Receptor Is Required for Akt Activation and Suppression of Anoikis in Cells Transformed by the ETV6-NTRK3 Chimeric Tyrosine Kinase. Mol. Cell. Biol., March 1, 2006; 26(5): 1754 - 1769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Lopez de Cicco, D. E. Bassi, S. Zucker, N. G. Seidah, and A. J.P. Klein-Szanto Human Carcinoma Cell Growth and Invasiveness Is Impaired by the Propeptide of the Ubiquitous Proprotein Convertase Furin Cancer Res., May 15, 2005; 65(10): 4162 - 4171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Miyamoto, M. Nakamura, K. Shitara, K. Nakamura, Y. Ohki, G. Ishii, M. Goya, K. Kodama, T. Sangai, H. Maeda, et al. Blockade of Paracrine Supply of Insulin-Like Growth Factors Using Neutralizing Antibodies Suppresses the Liver Metastasis of Human Colorectal Cancers Clin. Cancer Res., May 1, 2005; 11(9): 3494 - 3502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. H. Ibrahim and D. Yee Insulin-Like Growth Factor-I and Breast Cancer Therapy Clin. Cancer Res., January 15, 2005; 11(2): 944s - 950s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nakamura, S. Miyamoto, H. Maeda, S.-c. Zhang, T. Sangai, G. Ishii, T. Hasebe, Y. Endoh, N. Saito, M. Asaka, et al. Low Levels of Insulin-Like Growth Factor Type 1 Receptor Expression at Cancer Cell Membrane Predict Liver Metastasis in Dukes' C Human Colorectal Cancers Clin. Cancer Res., December 15, 2004; 10(24): 8434 - 8441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Samani, E. Chevet, L. Fallavollita, J. Galipeau, and P. Brodt Loss of Tumorigenicity and Metastatic Potential in Carcinoma Cells Expressing the Extracellular Domain of the Type 1 Insulin-Like Growth Factor Receptor Cancer Res., May 15, 2004; 64(10): 3380 - 3385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Colao, D. Ferone, P. Marzullo, and G. Lombardi Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management Endocr. Rev., February 1, 2004; 25(1): 102 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.'i. Miyamoto, K. Yano, S. Sugimoto, G. Ishii, T. Hasebe, Y. Endoh, K. Kodama, M. Goya, T. Chiba, and A. Ochiai Matrix Metalloproteinase-7 Facilitates Insulin-Like Growth Factor Bioavailability through Its Proteinase Activity on Insulin-Like Growth Factor Binding Protein 3 Cancer Res., January 15, 2004; 64(2): 665 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sekharam, H. Zhao, M. Sun, Q. Fang, Q. Zhang, Z. Yuan, H. C. Dan, D. Boulware, J. Q. Cheng, and D. Coppola Insulin-like Growth Factor 1 Receptor Enhances Invasion and Induces Resistance to Apoptosis of Colon Cancer Cells through the Akt/Bcl-xL Pathway Cancer Res., November 15, 2003; 63(22): 7708 - 7716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Blum, A. Gazit, and A. Levitzki Development of New Insulin-like Growth Factor-1 Receptor Kinase Inhibitors Using Catechol Mimics J. Biol. Chem., October 17, 2003; 278(42): 40442 - 40454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yasumaru, S. Tsuji, M. Tsujii, T. Irie, M. Komori, A. Kimura, T. Nishida, Y. Kakiuchi, N. Kawai, H. Murata, et al. Inhibition of Angiotensin II Activity Enhanced the Antitumor Effect of Cyclooxygenase-2 Inhibitors via Insulin-Like Growth Factor I Receptor Pathway Cancer Res., October 15, 2003; 63(20): 6726 - 6734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Min, Y. Adachi, H. Yamamoto, H. Ito, F. Itoh, C.-T. Lee, S. Nadaf, D. P. Carbone, and K. Imai Genetic Blockade of the Insulin-like Growth Factor-I Receptor: A Promising Strategy for Human Pancreatic Cancer Cancer Res., October 1, 2003; 63(19): 6432 - 6441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tang, D. Zhang, L. Fallavollita, and P. Brodt Vascular Endothelial Growth Factor C Expression and Lymph Node Metastasis Are Regulated by the Type I Insulin-like Growth Factor Receptor Cancer Res., March 15, 2003; 63(6): 1166 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Burroughs, J. Oh, J. C. Barrett, and R. P. DiAugustine Phosphatidylinositol 3-Kinase and Mek1/2 Are Necessary for Insulin-Like Growth Factor-I-Induced Vascular Endothelial Growth Factor Synthesis in Prostate Epithelial Cells: A Role for Hypoxia-Inducible Factor-1? Mol. Cancer Res., February 1, 2003; 1(4): 312 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Reiss, X. Tu, G. Romano, F. Peruzzi, J. Y. Wang, and R. Baserga Intracellular Association of a Mutant Insulin-like Growth Factor Receptor with Endogenous Receptors Clin. Cancer Res., July 1, 2001; 7(7): 2134 - 2144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Benini, M. C. Manara, N. Baldini, V. Cerisano, Massimo Serra, M. Mercuri, P.-L. Lollini, P. Nanni, P. Picci, and K. Scotlandi Inhibition of Insulin-like Growth Factor I Receptor Increases the Antitumor Activity of Doxorubicin and Vincristine against Ewing's Sarcoma Cells Clin. Cancer Res., June 1, 2001; 7(6): 1790 - 1797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Andrews, M. Resnicoff, A. E. Flanders, L. Kenyon, M. Curtis, G. Merli, R. Baserga, G. Iliakis, and R. D. Aiken Results of a Pilot Study Involving the Use of an Antisense Oligodeoxynucleotide Directed Against the Insulin-Like Growth Factor Type I Receptor in Malignant Astrocytomas J. Clin. Oncol., April 15, 2001; 19(8): 2189 - 2200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Peruzzi, M. Prisco, M. Dews, P. Salomoni, E. Grassilli, G. Romano, B. Calabretta, and R. Baserga Multiple Signaling Pathways of the Insulin-Like Growth Factor 1 Receptor in Protection from Apoptosis Mol. Cell. Biol., October 1, 1999; 19(10): 7203 - 7215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chott, Z. Sun, D. Morganstern, J. Pan, T. Li, M. Susani, I. Mosberger, M. P. Upton, G. J. Bubley, and S. P. Balk Tyrosine Kinases Expressed in Vivo by Human Prostate Cancer Bone Marrow Metastases and Loss of the Type 1 Insulin-Like Growth Factor Receptor Am. J. Pathol., October 1, 1999; 155(4): 1271 - 1279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Xie, B. Skytting, G. Nilsson, B. Brodin, and O. Larsson Expression of Insulin-like Growth Factor-1 Receptor in Synovial Sarcoma: Association with an Aggressive Phenotype Cancer Res., August 1, 1999; 59(15): 3588 - 3591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. W. Weston, K. M. Hiller, J. P. Mayben, G. A. Manousos, K. M. Bendt, R. Liu, and J. C. Cusack Jr. Expression of Human {{alpha}}(1,3)Fucosyltransferase Antisense Sequences Inhibits Selectin-mediated Adhesion and Liver Metastasis of Colon Carcinoma Cells Cancer Res., May 1, 1999; 59(9): 2127 - 2135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yoshimoto, H. Ishihara, A. Ohtsuru, K. Akino, R. Murakami, H. Kuroda, H. Namba, M. Ito, T. Fujii, and S. Yamashita Overexpression of Insulin-Like Growth Factor-1 (IGF-I) Receptor and the Invasiveness of Cultured Keloid Fibroblasts Am. J. Pathol., March 1, 1999; 154(3): 883 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Warren, H. Yuan, M. R. Matli, N. Ferrara, and D. B. Donner Induction of Vascular Endothelial Growth Factor by Insulin-like Growth Factor 1in Colorectal Carcinoma J. Biol. Chem., November 15, 1996; 271(46): 29483 - 29488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Li, M. Resnicoff, and R. Baserga Effect of Mutations at Serines 1280-1283 on the Mitogenic and Transforming Activities of the Insulin-like Growth Factor I Receptor J. Biol. Chem., May 24, 1996; 271(21): 12254 - 12260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Miura, E. Surmacz, J.-L. Burgaud, and R. Baserga Different Effects on Mitogenesis and Transformation of a Mutation at Tyrosine 1251 of the Insulin-like Growth Factor I Receptor J. Biol. Chem., September 22, 1995; 270(38): 22639 - 22644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Horney, C. A. Evangelista, and S. A. Rosenzweig Synthesis and Characterization of Insulin-like Growth Factor (IGF)-1 Photoprobes Selective for the IGF-binding Proteins (IGFBPs). PHOTOAFFINITY LABELING OF THE IGF-BINDING DOMAIN ON IGFBP-2 J. Biol. Chem., January 19, 2001; 276(4): 2880 - 2889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-M. Khatib, G. Siegfried, A. Prat, J. Luis, M. Chretien, P. Metrakos, and N. G. Seidah Inhibition of Proprotein Convertases Is Associated with Loss of Growth and Tumorigenicity of HT-29 Human Colon Carcinoma Cells. IMPORTANCE OF INSULIN-LIKE GROWTH FACTOR-1 (IGF-1) RECEPTOR PROCESSING IN IGF-1-MEDIATED FUNCTIONS J. Biol. Chem., August 10, 2001; 276(33): 30686 - 30693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Brodt, L. Fallavollita, A.-M. Khatib, A. A. Samani, and D. Zhang Cooperative Regulation of the Invasive and Metastatic Phenotypes by Different Domains of the Type I Insulin-like Growth Factor Receptor beta Subunit J. Biol. Chem., August 31, 2001; 276(36): 33608 - 33615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ligensa, S. Krauss, D. Demuth, R. Schumacher, J. Camonis, G. Jaques, and K. M. Weidner A PDZ Domain Protein Interacts with the C-terminal Tail of the Insulin-like Growth Factor-1 Receptor but Not with the Insulin Receptor J. Biol. Chem., August 31, 2001; 276(36): 33419 - 33427. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
